Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies.
Angiogenesis Inhibitors
/ administration & dosage
Animals
Antineoplastic Agents
/ administration & dosage
Drug Development
/ methods
Gastrointestinal Neoplasms
/ drug therapy
Humans
Neovascularization, Pathologic
/ drug therapy
Protein Binding
/ physiology
Protein Kinase Inhibitors
/ administration & dosage
Vascular Endothelial Growth Factor A
/ metabolism
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
17
1
2019
medline:
30
6
2019
entrez:
17
1
2019
Statut:
ppublish
Résumé
Angiogenesis is an essential process for tumor growth and metastasis. Inhibition of angiogenesis as an anticancer strategy has shown significant results in a plethora of tumors. Anti-angiogenic agents are currently part of many standard-of-care options for several metastatic gastrointestinal cancers. Bevacizumab, aflibercept, ramucirumab, and regorafenib have significantly improved both progression-free and overall survival in different lines of treatment in metastatic colorectal cancer. Second-line ramucirumab and third-line apatinib are effective anti-angiogenic treatments for patients with metastatic gastric cancer. Unfortunately, the anti-angiogenic strategy has major practical limitations: resistance inevitably develops through redundancy of signaling pathways and selection for subclonal populations adapted for hypoxic conditions. Anti-angiogenic agents may be more effective in combination therapies, with not only cytotoxics but also other emerging compounds in the anti-angiogenic class or in the separate class of the so-called vascular-disrupting agents. This review aims to provide an overview of the approved and "under development" anti-angiogenic compounds as well as the vascular-disrupting agents in the treatment of gastrointestinal cancers, focusing on the actual body of knowledge available on therapy challenges, pharmacodynamic and pharmacokinetic mechanisms, safety profiles, promising predictive biomarkers, and future perspectives.
Identifiants
pubmed: 30649744
doi: 10.1007/s40264-018-0776-6
pii: 10.1007/s40264-018-0776-6
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
159-179Références
J Clin Oncol. 2011 May 20;29(15):2004-10
pubmed: 21464401
Oncologist. 2011;16(8):1120-30
pubmed: 21742963
J Clin Oncol. 2009 Jul 1;27(19):3154-60
pubmed: 19451429
Breast Cancer Res Treat. 2010 Jul;122(1):181-8
pubmed: 20361252
J Clin Oncol. 2010 Feb 10;28(5):780-7
pubmed: 20048182
Int J Cancer. 1995 Sep 27;63(1):119-23
pubmed: 7558438
J Clin Oncol. 2011 Aug 1;29(22):2965-71
pubmed: 21709202
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Br J Cancer. 2003 Jun 16;88(12):1979-86
pubmed: 12799646
Br J Cancer. 2012 May 22;106(11):1722-7
pubmed: 22568966
Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):443-50
pubmed: 11173139
J Clin Oncol. 2013 Sep 10;31(26):3219-25
pubmed: 23918952
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6
pubmed: 23045683
Curr Med Chem. 2017;24(28):3068-3076
pubmed: 28494743
Expert Opin Pharmacother. 2017 Aug;18(11):1153-1162
pubmed: 28649871
BMC Cancer. 2016 Jul 07;16:412
pubmed: 27389564
Nat Rev Cancer. 2008 Aug;8(8):579-91
pubmed: 18596824
PLoS One. 2013 Jul 04;8(7):e66774
pubmed: 23861747
Expert Rev Anticancer Ther. 2015 May;15(5):579-94
pubmed: 25831142
J Clin Oncol. 2013 Apr 1;31(10):1341-7
pubmed: 23358972
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Nat Rev Cancer. 2005 Jun;5(6):423-35
pubmed: 15928673
Cancer J. 2016 May-Jun;22(3):182-9
pubmed: 27341596
J Hematol Oncol. 2017 Sep 5;10(1):153
pubmed: 28870253
J Clin Oncol. 2016 May 1;34(13):1448-54
pubmed: 26884585
Drug Saf. 2017 Nov;40(11):1131-1140
pubmed: 28585152
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Clin Cancer Res. 2004 Jan 15;10(2):415-27
pubmed: 14760060
Oncologist. 2009 Jan;14(1):22-8
pubmed: 19144677
Eur J Clin Pharmacol. 2014 Aug;70(8):893-906
pubmed: 24858820
Nat Rev Clin Oncol. 2016 May;13(5):268-70
pubmed: 27071350
Cancer Chemother Pharmacol. 2017 Sep;80(3):599-608
pubmed: 28744667
Am J Hypertens. 2010 May;23(5):460-8
pubmed: 20186127
Nat Rev Mol Cell Biol. 2006 May;7(5):359-71
pubmed: 16633338
Cancer Microenviron. 2015 Apr;8(1):15-21
pubmed: 25326055
Br J Cancer. 2014 Sep 9;111(6):1122-31
pubmed: 25072258
Jpn J Clin Oncol. 2016 Nov 1;46(11):1000-1007
pubmed: 27566973
Lancet. 2006 Oct 14;368(9544):1329-38
pubmed: 17046465
Clin Cancer Res. 2013 Feb 15;19(4):929-37
pubmed: 23169435
Invest New Drugs. 2017 Aug;35(4):518-523
pubmed: 28285368
Jpn J Cancer Res. 1999 Dec;90(12):1387-95
pubmed: 10665658
Angiogenesis. 2012 Jun;15(2):171-85
pubmed: 22302382
Ann Oncol. 2015 Oct;26(10):2085-91
pubmed: 26272806
Cancer Chemother Pharmacol. 2012 Jul;70(1):65-74
pubmed: 22623210
Crit Rev Oncol Hematol. 2016 Apr;100:99-106
pubmed: 26907512
Oncologist. 2009 Jun;14(6):612-20
pubmed: 19474164
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
Oncotarget. 2017 Jun 27;8(26):42949-42961
pubmed: 28487489
Eur J Cancer. 2015 May;51(8):942-9
pubmed: 25818084
Biochem J. 1937 Mar;31(3):454-60
pubmed: 16746357
Cancer Res. 2002 Jun 15;62(12):3408-16
pubmed: 12067983
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Ann Oncol. 2015 Jun;26(6):1230-1237
pubmed: 25787923
Cancer Invest. 2017 Sep 14;35(8):519-534
pubmed: 28872367
BMC Cancer. 2015 Sep 22;15:643
pubmed: 26394830
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):416-20
pubmed: 15701823
Ann Oncol. 2013 Jun;24(6):1560-7
pubmed: 23493136
Invest New Drugs. 2008 Apr;26(2):159-67
pubmed: 18219445
Cancer Res. 2010 Aug 1;70(15):6171-80
pubmed: 20631075
Science. 2005 Jan 7;307(5706):58-62
pubmed: 15637262
Cancer Treat Rev. 2017 Feb;53:120-127
pubmed: 28104567
Lancet Oncol. 2015 May;16(5):499-508
pubmed: 25877855
Int J Hyperthermia. 2015;31(5):453-9
pubmed: 25915829
Ann Oncol. 2015 Apr;26(4):724-730
pubmed: 25600568
Clin Colorectal Cancer. 2016 Mar;15(1):91-94.e1
pubmed: 26603056
Cancer Chemother Pharmacol. 2017 Apr;79(4):661-671
pubmed: 28314990
Clin Exp Immunol. 2013 Jun;172(3):500-6
pubmed: 23600839
Cancer Res. 1999 Apr 1;59(7):1626-34
pubmed: 10197639
Lancet Oncol. 2012 Sep;13(9):897-905
pubmed: 22898678
Cancer. 2013 Jul 15;119(14):2639-44
pubmed: 23589078
JAMA. 2018 Jun 26;319(24):2486-2496
pubmed: 29946728
Lancet Oncol. 2015 Jun;16(6):619-29
pubmed: 25981818
Lancet Oncol. 2015 Jun;16(6):695-703
pubmed: 25956795
Target Oncol. 2015 Jun;10(2):199-213
pubmed: 25213039
Ann Oncol. 2017 Sep 01;28(9):2128-2134
pubmed: 28911067
J Clin Oncol. 2016 Aug 10;34(23):2728-35
pubmed: 27325864
Lancet Oncol. 2013 Nov;14(12):1233-42
pubmed: 24140184
Expert Rev Anticancer Ther. 2018 Mar;18(3):251-266
pubmed: 29338550
Oncogene. 2005 Apr 14;24(16):2647-53
pubmed: 15735759
Expert Rev Clin Pharmacol. 2016 Jul;9(7):877-85
pubmed: 27149032
Clin Hemorheol Microcirc. 2013;54(4):345-55
pubmed: 23241508
Nat Rev Clin Oncol. 2012 Apr 10;9(6):327-37
pubmed: 22473096
J Clin Oncol. 2011 May 20;29(15):1997-2003
pubmed: 21464406
Ann Oncol. 2018 Mar 1;29(3):602-609
pubmed: 29228087
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
J Clin Oncol. 2008 Jul 10;26(20):3403-10
pubmed: 18612155
Gastroenterol Res Pract. 2016;2016:9189483
pubmed: 27656206
Biochem Biophys Res Commun. 1994 Nov 30;205(1):728-38
pubmed: 7999104
Nat Rev Cancer. 2010 Feb;10(2):138-46
pubmed: 20094048
Lancet. 2016 Jul 30;388(10043):518-29
pubmed: 26853587
Am Health Drug Benefits. 2016 Jun;9(4):221-32
pubmed: 27688834
Clin Colorectal Cancer. 2005 Sep;5(3):188-96
pubmed: 16197622
Clin Cancer Res. 2010 Aug 1;16(15):3887-900
pubmed: 20554752
Lancet. 2014 Jul 26;384(9940):319-28
pubmed: 24768112
J Am Soc Hypertens. 2018 Jun;12(6):409-425
pubmed: 29703600
J Clin Oncol. 2012 Oct 1;30(28):3499-506
pubmed: 22949147
Drug Resist Updat. 2016 Mar;25:26-37
pubmed: 27155374
Clin Lung Cancer. 2011 Jan;12(1):18-25
pubmed: 21273175
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
Science. 2015 Aug 14;349(6249):694-5
pubmed: 26273044
Int J Hematol. 2012 Jan;95(1):1-2
pubmed: 22170230
Oncotarget. 2014 Jul 15;5(13):4709-21
pubmed: 25015210
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
Lancet. 2013 May 4;381(9877):1537
pubmed: 23642696
J Clin Pharmacol. 2014 May;54(5):495-502
pubmed: 24382596
Lancet. 2013 Jan 26;381(9863):295-302
pubmed: 23177515
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Thyroid. 2013 Feb;23(2):151-9
pubmed: 23398161
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
Cancer Res Treat. 2017 Oct;49(4):851-868
pubmed: 28052652
J Nephrol. 2013 Sep-Oct;26(5):807-10
pubmed: 24052461
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8
pubmed: 12177445
N Engl J Med. 2008 May 8;358(19):2039-49
pubmed: 18463380
Cancer Manag Res. 2013 Jun 11;5:103-15
pubmed: 23807861
N Engl J Med. 2013 Nov 7;369(19):1783-96
pubmed: 24180494
Ann Oncol. 2017 Dec 01;28(12):2932-2942
pubmed: 28950290
Nat Clin Pract Oncol. 2006 Dec;3(12):682-92
pubmed: 17139319
J Clin Oncol. 2012 Oct 10;30(29):3588-95
pubmed: 22965961
Int J Cancer. 2011 Oct 15;129(8):1963-9
pubmed: 21154746
Med Res Rev. 2018 Sep;38(5):1674-1705
pubmed: 29878411
Int J Cancer. 2002 May 1;99(1):1-6
pubmed: 11948484
Curr Med Chem. 2014;21(8):1039-49
pubmed: 23992324
Br J Cancer. 2013 Feb 19;108(3):503-11
pubmed: 23361051
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Lancet Oncol. 2010 Oct;11(10):962-72
pubmed: 20851682
Curr Opin Pharmacol. 2015 Apr;21:7-13
pubmed: 25500206
Lancet Oncol. 2015 May;16(5):531-40
pubmed: 25864104
Oncogene. 2014 Apr 3;33(14):1743-54
pubmed: 23604130
Lancet Oncol. 2013 Jan;14(1):29-37
pubmed: 23168366
J Hematol Oncol. 2017 Jan 19;10(1):22
pubmed: 28103904
Eur J Cancer. 2007 Jan;43(1):55-63
pubmed: 17095207
Cancer Res. 2001 Sep 1;61(17):6413-22
pubmed: 11522635
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
Cancer Treat Rev. 2017 Sep;59:123-131
pubmed: 28818671
Invest New Drugs. 2013 Aug;31(4):881-90
pubmed: 23325291
Cancer. 2015 Jan 15;121(2):311-9
pubmed: 25236375
Br J Cancer Suppl. 1996 Jul;27:S86-8
pubmed: 8763854
Cancer Immunol Immunother. 2008 Jan;57(1):97-106
pubmed: 17602225
Nat Rev Clin Oncol. 2013 Nov;10(11):643-55
pubmed: 24061039
J Clin Oncol. 2011 Oct 20;29(30):3968-76
pubmed: 21844504
Cancer Chemother Pharmacol. 2017 Sep;80(3):487-495
pubmed: 28695268
Nat Rev Drug Discov. 2004 May;3(5):391-400
pubmed: 15136787
Clin Sci (Lond). 2012 May 1;122(10):449-57
pubmed: 22142330
Ann Oncol. 2012 Jan;23(1):119-127
pubmed: 21447616
Pharmacol Res. 2016 Sep;111:592-599
pubmed: 27438459
Farm Hosp. 2007 Jul-Aug;31(4):256-7
pubmed: 18052624
Cancer Chemother Pharmacol. 2016 Aug;78(2):433-41
pubmed: 27379498
Cancer Res. 2006 Dec 15;66(24):11520-39
pubmed: 17178843
Cancer Sci. 2011 Jul;102(7):1374-80
pubmed: 21443688